1-20 of 45
Violeta Serra
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Harnessing STING Signaling and Natural Killer Cells overcomes PARP Inhibitor Resistance in Homologous Recombination Deficient Breast Cancer

Flaminia Pedretti, Mohmed Abdalfttah, Benedetta Pellegrino, Francesca Mateo, Paula Martínez-Sanz, Andrea Herencia-Ropero, Andreu Òdena, Pau Clavell-Revelles, Giorgia Casali, Heura Domenech, Laia Monserrat, Dražen Papić, Alba Mas Malavila, Anna Pascual-Reguant, Herena Eixarch, Marta Guzman, Olga Rodriguez, Judit Grueso, Sara Simonetti, Roberta Fasani, Paolo Nuciforo, Carmen Espejo, Stefan Florian, Miguel Ángel Pujana, Lara Nonell, Joan Seoane, Viia Valge-Archer, Mark J. O'Connor, Juan C. Nieto, Holger Heyn, Judith Balmaña, Alba Llop-Guevara, Violeta Serra
Journal: Cancer Research
Cancer Res (2025)
https://doi.org/10.1158/0008-5472.CAN-24-2531
Published: 11 March 2025
View article titled, Harnessing STING Signaling and Natural Killer Cells overcomes PARP Inhibitor Resistance in Homologous Recombination Deficient Breast Cancer
Open the PDF for Harnessing STING Signaling and Natural Killer Cells overcomes PARP Inhibitor Resistance in Homologous Recombination Deficient Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract RF01-05: Functional assessment of RAD51 foci and replication fork dynamics in PARPi resistant BRCA1/2 mutated breast cancer

Elizabeth Harvey-Jones, Maya Raghunandan, Luisa Robbez-Masson, Thanussuyah Alaguthurai, Alba Llop-Guevara, Jennifer Trendell, Olga Rodriguez, Marta Guzman, Daniel Weekes, Christelle deRenty, Eleanor Knight, Rebecca Marlow, Christopher Starling, Ruifang Liu, Nivedita Ravindran, Ioannis Roxanis, Natalia Lukashchuk, Violeta Serra, Stephen Pettitt, Christopher Lord, Andrew NJ Tutt
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): RF01-05.
https://doi.org/10.1158/1538-7445.SABCS23-RF01-05
Published: 02 May 2024
View article titled, Abstract RF01-05: Functional assessment of RAD51 foci and replication fork dynamics in PARPi resistant BRCA1/2 mutated breast cancer
Journal Articles

Abstract PO2-03-09: Cost-effectiveness analysis of RAD51 functional biomarker for platinum sensitivity in the GeparSixto trial

Isabel Pimentel, Carles Forné, Alba Llop-Guevara, Misericòrdia Carles-Lavila, Violeta Serra, Montserrat Rué, Judith Balmaña
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO2-03-09.
https://doi.org/10.1158/1538-7445.SABCS23-PO2-03-09
Published: 02 May 2024
View article titled, Abstract PO2-03-09: Cost-effectiveness analysis of RAD51 functional biomarker for platinum sensitivity in the GeparSixto trial
Journal Articles

Abstract 2493: Prospective evaluation of predictive biomarkers for Palbociclib (P) and endocrine therapy (ET) benefit in hormone receptor (HR)-positive [+]/human epidermal growth factor receptor 2 (HER2)-negative [-] advanced breast cancer (ABC) patients (pts) from PARSIFAL clinical trial: The transFAL sub-study

Joan Albanell, Angelo Gámez Pozo, Carlos L. Arteaga, Meritxell Bellet, Federico Rojo, Abel González, Beatriz Bellosillo, Violeta Serra, Petra Gener, José Antonio Guerrero, Laura López-Montero, Mario Mancino, Jose Rodríguez-Morató, Leonardo Mina, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2493.
https://doi.org/10.1158/1538-7445.AM2024-2493
Published: 22 March 2024
View article titled, Abstract 2493: Prospective evaluation of predictive biomarkers for Palbociclib (P) and endocrine therapy (ET) benefit in hormone receptor (HR)-positive [+]/human epidermal growth factor receptor 2 (HER2)-negative [-] advanced breast cancer (ABC) patients (pts) from PARSIFAL clinical trial: The transFAL sub-study
Journal Articles

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana Ros, Azadeh Cheraghchi-Bashi, Jelena Urosevic, Sophie D'Arcy, Oona Delpuech, Michelle DuPont, David I. Fisher, Eric T. Gangl, Hilary Lewis, Dawn Trueman, Neha Wali, Stuart C. Williamson, Jennifer Moss, Elodie Montaudon, Heloise Derrien, Elisabetta Marangoni, Ricardo J. Miragaia, Sladjana Gagrica, Pablo Morentin-Gutierrez, Thomas A. Moss, Gareth Maglennon, Daniel Sutton, Radoslaw Polanski, Alan Rosen, Jonathan Cairns, Pei Zhang, Mònica Sánchez-Guixé, Violeta Serra, Susan E. Critchlow, James S. Scott, Justin P.O. Lindemann, Simon T. Barry, Teresa Klinowska, Christopher J. Morrow, Larissa S. Carnevalli
Journal: Cancer Research
Cancer Res (2023) 83 (23): 3989–4004.
https://doi.org/10.1158/0008-5472.CAN-23-0694
Published: 01 December 2023
View article titled, The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance
Open the PDF for The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER<sup>+</sup> Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

Annalisa Petrelli, Sabrina Rizzolio, Filippo Pietrantonio, Sara E. Bellomo, Matteo Benelli, Loris De Cecco, Dario Romagnoli, Enrico Berrino, Claudia Orrù, Salvatore Ribisi, Daniel Moya-Rull, Cristina Migliore, Daniela Conticelli, Irene M. Maina, Elisabetta Puliga, Violeta Serra, Benedetta Pellegrino, Alba Llop-Guevara, Antonino Musolino, Salvatore Siena, Andrea Sartore-Bianchi, Michele Prisciandaro, Federica Morano, Maria Antista, Uberto Fumagalli, Giovanni De Manzoni, Maurizio Degiuli, Gian Luca Baiocchi, Marco F. Amisano, Alessandro Ferrero, Caterina Marchiò, Simona Corso, Silvia Giordano
Journal: Cancer Research
Cancer Res (2023) 83 (10): 1699–1710.
https://doi.org/10.1158/0008-5472.CAN-22-2620
Published: 15 May 2023
View article titled, <em>BRCA2</em> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
Open the PDF for <em>BRCA2</em> Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract OT3-11-02: SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA TRIAL

Judith Balmaña, Tomás Pascual, Alba Llop-Guevara, Pablo Tolosa, Isabel Blancas, Maria-Eva Perez-Lopez, Barbara Adamo, Iris Teruel, Jose Ponce, Marta Gonzalez, Gemma Viñas, Laura Lema, Francisco Javier Salvador, Mª Teresa Martinez, Alejandra Espinosa, Aleix Prat, Violeta Serra
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT3-11-02.
https://doi.org/10.1158/1538-7445.SABCS22-OT3-11-02
Published: 01 March 2023
View article titled, Abstract OT3-11-02: SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA TRIAL
Journal Articles

Abstract P6-10-04: Homologous recombination deficiency across subtypes of primary breast cancer

Christina Engebrethsen, Synnøve Yndestad, Andrea Herencia-Ropero, Oleksii Nikolaienko, Olav Karsten Vintermyr, Reidun K. Lillestøl, Laura Minsaas, Beryl Leirvaag, Gjertrud Iversen, Bjørnar Gilje, Egil Blix, Helge Espelid, Steinar Lundgren, Jürgen Geisler, Liv Jorunn Vassbotn, Hildegunn S. Aase, Turid Aas, Alba Llop-Guevara, Violeta Serra, Per Eystein Lønning, Stian Knappskog, Hans Petter Eikesdal
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P6-10-04.
https://doi.org/10.1158/1538-7445.SABCS22-P6-10-04
Published: 01 March 2023
View article titled, Abstract P6-10-04: Homologous recombination deficiency across subtypes of primary breast cancer
Journal Articles

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop-Guevara, Flaminia Pedretti, Alejandro Moles-Fernández, Cristina Viaplana, Guillermo Villacampa, Marta Guzmán, Olga Rodríguez, Judit Grueso, Jose Jiménez, Enrique J. Arenas, Andrea Degasperi, João M.L. Dias, Josep V. Forment, Mark J. O'Connor, Olivier Déas, Stefano Cairo, Yinghui Zhou, Antonino Musolino, Carlos Caldas, Serena Nik-Zainal, Robert B. Clarke, Paolo Nuciforo, Orland Díez, Xavier Serres-Créixams, Vicente Peg, Martín Espinosa-Bravo, Teresa Macarulla, Ana Oaknin, Joaquin Mateo, Joaquín Arribas, Rodrigo Dienstmann, Meritxell Bellet, Mafalda Oliveira, Cristina Saura, Sara Gutiérrez-Enríquez, Judith Balmaña, Violeta Serra
Journal: Cancer Research
Cancer Res (2022) 82 (8): 1646–1657.
https://doi.org/10.1158/0008-5472.CAN-21-2409
Published: 15 April 2022
View article titled, Preclinical <em>In Vivo</em> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification
Open the PDF for Preclinical <em>In Vivo</em> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification in another window
Includes: Supplementary data
Journal Articles

Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3)

Aleix Prat, Juan M. Cejalvo, Laia Pare, Olga Martínez-Sáez, Mireia Margelí Vila, Claudette Falato, Josefina Cruz, Miriam Arumí de Dios, Maria J Vidal, Juan Antonio Guerra, Ana Maria Luna Barrera, Pablo Tolosa, Francisco Javier Salvador-Bofill, Sonia Pernas, Blanca Gonzáles-Farré, Esther Sanfeliu, Eva Ciruelos, Violeta Serra, Martin Espinosa-Bravo, Yann Izarzugaza, Stephen Esker, Pang-Dian Fan, Guillermo Villacampa, Juan M Ferrero-Cafiero, Tomás Pascual, Mafalda Oliveira
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD13-04.
https://doi.org/10.1158/1538-7445.SABCS21-PD13-04
Published: 15 February 2022
View article titled, Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3)
Journal Articles

Abstract P5-13-14: Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)

Andreu Òdena, Laia Monserrat, Fara Brasó-Maristany, Marta Guzmán, Judit Grueso, Olga Rodríguez, Maurizio Scaltriti, Sarat Chandarlapaty, Yang Qiu, Kumiko Koyama, Mafalda Oliveira, Aleix Prat, Violeta Serra
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P5-13-14.
https://doi.org/10.1158/1538-7445.SABCS21-P5-13-14
Published: 15 February 2022
View article titled, Abstract P5-13-14: Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)
Journal Articles

Abstract CT161: A homologous recombination repair (HRR) functional assay to stratify patients with metastatic prostate cancer for PARP inhibitor treatment in the TOPARP-B clinical trial

Sara Arce-Gallego, Alba Llop-Guevara, Suzanne Carreira, Nuria Porta, Roberta Fasani, Diletta Bianchini, George Seed, Pasquale Rescigno, Alec Paschalis, Claudia Bertan, Chloe Baker, Jane Goodall, Susana Miranda, Ruth Riisnaes, Ines Figueiredo, Ana Ferreira, Rita Pereira, Bora Gurel, Daniel Nava Rodrigues, Wei Yuan, Jan Rekowski, Emma Hall, Violeta Serra, Johann S. de Bono, Joaquin Mateo
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT161.
https://doi.org/10.1158/1538-7445.AM2021-CT161
Published: 01 July 2021
View article titled, Abstract CT161: A homologous recombination repair (HRR) functional assay to stratify patients with metastatic prostate cancer for PARP inhibitor treatment in the TOPARP-B clinical trial
Journal Articles

Abstract 2817: Metabolic heterogeneity in breast cancer integrative clusters to screen metabolic vulnerabilities for diagnosis and treatment response

Susana Ros, Alan J. Wright, Flaviu Bulat, Wendy Greenwood, De-en Hu, Maurizio Callari, Ming Li Chia, Violeta Serra, Oscar Rueda, Alejandra Bruna, Carlos Caldas, Kevin M. Brindle
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2817.
https://doi.org/10.1158/1538-7445.AM2021-2817
Published: 01 July 2021
View article titled, Abstract 2817: Metabolic heterogeneity in breast cancer integrative clusters to screen metabolic vulnerabilities for diagnosis and treatment response
Journal Articles

Abstract 364: The RAD51-FFPE test rapidly and reliably identifies homologous recombination deficient ovarian and endometrial carcinomas

Lise M. van Wijk, Claire J. Kramer, Sylvia Vermeulen, Natalja T. ter Haar, Cor D. de Kroon, Marthe M. de Jonge, Katja N. Gaarenstroom, Harry Vrieling, Violeta Serra, Tjalling Bosse, Maaike P. Vreeswijk
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 364.
https://doi.org/10.1158/1538-7445.AM2021-364
Published: 01 July 2021
View article titled, Abstract 364: The RAD51-FFPE test rapidly and reliably identifies homologous recombination deficient ovarian and endometrial carcinomas
Journal Articles

Abstract 1685: The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts

Emilie Vinolo, Joaquin Arribas, Andrea Bertotti, Alejandra Bruna, Annette T. Byrne, Robert B. Clarke, Nathalie Conte, Steven de Jong, Didier Decaudin, Zdenka Dudova, Jos Jonkers, Daniela Krasser, Ales Krenek, Luisa Lanfrancone, Eleonora Leucci, Elisabetta Marangoni, Gunhild Mari Maelandsmo, Michaela Th. Mayrhofer, Terrence F. Meehan, Jens Henrik Norum, Hector G. Palmer, Alejandro Piris Gimenez, Leo Price, Sergio Roman-Roman, Francesca Sarno, Violeta Serra, Laura Soucek, Livio Trusolino, Marieke van de Ven, Luca Vezzadini, Alberto Villanueva, Andrea Wutte, Enzo Medico, on behalf of the EurOPDX Research Infrastructure
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1685.
https://doi.org/10.1158/1538-7445.AM2020-1685
Published: 15 August 2020
View article titled, Abstract 1685: The EurOPDX Research Infrastructure: Supporting European and worldwide cancer research with patient-derived xenografts
Journal Articles

Abstract 1118: Absence of mouse-specific tumor evolution in patient-derived cancer xenografts

Jessica Giordano, Xing Yi Woo, Anuj Srivastava, Zi-Ming Zhao, Michael W. Lloyd, Roebi de Bruijn, Yun-Suhk Suh, Francesco Galimi, Andrea Bertotti, Adam Lafferty, Alice C. O'Farrell, Elodie Modave, Diether Lambrechts, Petra ter Brugge, Violeta Serra, Elisabetta Marangoni, Rania El Botty, Jong-Il Kim, Han-Kwang Yang, Charles Lee, Dennis A. Dean, Brandi Davis-Dusenbery, Yvonne A. Evrard, James H. Doroshow, Alana L. Welm, Bryan E. Welm, Michael T. Lewis, Bingliang Fang, Jack Roth, Funda Meric-Bernstam, Meenhard Herlyn, Michael Davies, Li Ding, Shunqiang Li, Ramaswamy Govindan, Jeffrey A. Moscow, Carol J. Bult, Claudio Isella, Livio Trusolino, Annette T. Byrne, Jos Jonkers, Jeffrey H. Chuang, Enzo Medico, EurOPDX consortium & PDXNET consortium
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1118.
https://doi.org/10.1158/1538-7445.AM2020-1118
Published: 15 August 2020
View article titled, Abstract 1118: Absence of mouse-specific tumor evolution in patient-derived cancer xenografts
Journal Articles

Abstract 1282: Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer

Marc Cosín, Tian Tian, Winona Oliveros, Olesya A. Kharenko, Edward H. van der Horst, Reena G. Patel, Cyrus Calosing, Eric Campeau, Ravi Jahagirdar, Sanjay Lakhotia, Marta Melé, Marta Palafox, Joaquín Arribas, Mafalda Oliveira, Cristina Saura, Violeta Serra, Sandra Peiro
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 1282.
https://doi.org/10.1158/1538-7445.AM2020-1282
Published: 15 August 2020
View article titled, Abstract 1282: Overcoming resistance to inhibitors of CDK4/6 and BET in estrogen receptor-positive breast cancer
Journal Articles

Abstract P4-10-17: Baseline and pharmacodynamic changes of circulating exosomal microRNAs predict early versus late progression to palbociclib plus endocrine therapy in patients with metastatic breast cancer. A sub-analysis of the PARSIFAL-1 trial

David Casadevall, Joan Albanell Mestres, Federico Rojo, Beatríz Bellosillo, Abel González, Violeta Serra, Meritxell Bellet, Miguel Angel Gil, Miquel Angel Pujana, Angelo Gámez, Enrique Espinosa, Peter Schmid, Joseph Gligorov, Frederik Marmé, Carlos L. Arteaga, Leonardo Mina, Andrea Malfettone, Miguel Sampayo, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P4-10-17.
https://doi.org/10.1158/1538-7445.SABCS19-P4-10-17
Published: 15 February 2020
View article titled, Abstract P4-10-17: Baseline and pharmacodynamic changes of circulating exosomal microRNAs predict early versus late progression to palbociclib plus endocrine therapy in patients with metastatic breast cancer. A sub-analysis of the PARSIFAL-1 trial
Journal Articles

Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

Jorge Gómez-Miragaya, Ander Díaz-Navarro, Raul Tonda, Sergi Beltran, Luis Palomero, Marta Palafox, Lacey E. Dobrolecki, Chen Huang, Suhas Vasaikar, Bing Zhang, Gerburg M. Wulf, Alejandro Collado-Sole, Eva M. Trinidad, Purificación Muñoz, Laia Paré, Aleix Prat, Alejandra Bruna, Carlos Caldas, Joaquín Arribas, María Teresa Soler-Monso, Anna Petit, Judith Balmaña, Cristina Cruz, Violeta Serra, Miguel Angel Pujana, Michael T. Lewis, Xose S. Puente, Eva González-Suárez
Journal: Cancer Research
Cancer Res (2019) 79 (16): 4258–4270.
https://doi.org/10.1158/0008-5472.CAN-18-3835
Published: 15 August 2019
View article titled, Chromosome 12p Amplification in Triple-Negative/<em>BRCA1-</em>Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity
Open the PDF for Chromosome 12p Amplification in Triple-Negative/<em>BRCA1-</em>Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity in another window
Includes: Supplementary data
Journal Articles

Abstract 321: Genome-wide CRISPR screens identify combination strategies for Capivasertib (AZD5363; AKT) and AZD8186 (PI3Kβ/δ) in PTEN-null breast cancer

Shanade Dunn, Jason Yu, Albert Gris-Oliver, James Pilling, Philip Hopcroft, Urs Yelland, Natalie Cureton, Anna Staniszewsla, Yan Zi Au, Swee Hoe Ong, Beverley Isherwood, Violeta Serra, Simon Barry, Barry R. Davies, James T. Lynch, Kosuke Yusa
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 321.
https://doi.org/10.1158/1538-7445.AM2019-321
Published: 01 July 2019
View article titled, Abstract 321: Genome-wide CRISPR screens identify combination strategies for Capivasertib (AZD5363; AKT) and AZD8186 (PI3Kβ/δ) in PTEN-null breast cancer